Delivering the Science of Tomorrow
In this white paper, we examine the vital role logistics play in this transformation, the impact future regulations will have on the pharma supply chain, reasons why there is a need for decentralized trials, and the benefits of implementing direct-to-patient delivery models.
This DHL report developed in collaboration with leading industry analyst Frost & Sullivan provides perspectives on how Contract Research Organizations (CRO’s) can achieve agility through collaboration and partnerships with key stakeholders in the pharmaceutical and logistics value chain.
The global clinical research market is undergoing a major transformation. The shift away from traditional to direct-to-patient clinical trials means addressing multiple focal coordination points that require pick-up and delivery within extremely tight timeframes and usually over long distances. Abiding by good distribution practices and storage standards and maintaining a secure chain of custody as per regional regulations are imperative.
New technologies, such as next-generation sequencing, artificial intelligence, multi-omics technology platforms, and single-use bio processors are enabling the shift toward the development of targeted therapies.
The need for frequent and lengthy site visits, disruption in personal routines, and exclusion due to geographic barriers make trial participation burdensome for patients, resulting in missed recruitment targets. Patient identification and outreach are significant drivers of the costs and inefficiencies of research.
Logistics solution providers need to incorporate automation, strengthen global cold chain networks, leverage data-driven demand planning solutions, and enhance data security frameworks to emerge as long-term partners to sponsors and CROs.
Delivering Clinical Trials of the Future
The goal of this paper is to act as a catalyst for further collaboration between clinical research organizations, pharmaceutical manufacturers, and supply chain and Logistics providers. If the pandemic has taught us anything is the importance of capable end-to-end logistics that service every component throughout the clinical development supply chain, in order to support the future of clinical trials.